NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-15
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
Living Fair Value by QuarterlyIQ
A valuation that evolves as the business changes.
A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.
View Living FV report and workflowThree key conditions need to be met for the investment thesis to play out.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Quarterly dividend increases to at least $1.34 per share | The company keeps raising its dividend, now $1.34 per share. | Intact | dividend per share falls below $1.30 quarterly | Required source inputs unavailable Cannot calculate Dividend per share from the available matching source inputs. Missing inputs are not treated as zero. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextNewly stated in 2026-Q1. Management committed to maintaining dividend growth with a 3.1% increase to $1.34 per share. No further quarterly data available to assess delivery or trajectory. Delivery assessment Oct 15, 2026 |
EPS reaches at least $11.55 in 2026 | A primary condition in Johnson & Johnson's published investment case. The stated target is >= $11.55 per share. | Broken | EPS falls below $10.85 per share in 2026 | Diluted EPS: $2.27 per share FY2026-Q2; GAAP. Published target: >= $11.55 per share. Target period is not explicitly aligned with this observation. Source published Jul 23, 20262.27 USD/share · source valueSource reportLast status assessment Oct 15, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 28, 2026 Source: company_financial_results. Reference: ffa58117-e476-4883-8224-37a41a22fcf7. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 4 of last 4 quarters. Adjusted EPS guidance increased from $10.79 in 2025 to $11.68 in 2026, an 8.2% rise at midpoint. Management has steadily raised EPS guidance throughout 2026, showing delivery on earnings growth. Delivery assessment Oct 15, 2026 |
Johnson & Johnson revenue reaches at least $100.8 billion in 2026 | Johnson & Johnson grows revenue to about $100.8 billion in 2026. | Under Pressure | revenue falls below $93.7 billion in 2026 | Revenue: $25.31B FY2026-Q2; GAAP. Published target: >= $100.8 billion. Target period is not explicitly aligned with this observation. Source published Jul 23, 202625,310,000,000 USD · source valueSource reportLast status assessment Oct 15, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 28, 2026 Source: company_financial_results. Reference: ffa58117-e476-4883-8224-37a41a22fcf7. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsLatest: 16 Buy / Strong Buy · 6 Hold · 1 Sell / Strong Sell
Recent actions · Sep 16–Oct 15 · 8 recorded
1 raises · 3 cuts · 0 unchanged · 2 without a comparable prior
Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This investment represents a durable compounder with a focus on steady growth. The current thesis state is intact, supported by strong recent financial performance and ongoing management priorities.
The market appears to be pricing in a stretched valuation with a durable premium compared to peers. There is an expectations gap, suggesting that some positive outcomes may not be fully reflected in the current valuation.
Fundamentals are likely to show steady growth as management is on track with revenue and earnings guidance. However, there is a mixed delivery on innovation and pipeline progress, which could impact long-term performance.
The long-term thesis hinges on management's ability to raise guidance and deliver on innovation. Additionally, external factors like sector performance and economic conditions will play a crucial role in shaping outcomes.
Overall, Johnson & Johnson's fundamentals and management execution suggest a stable outlook for the next 1 to 3 years. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.